ArticleBJUI compass2026
Survival outcomes in prostate cancer patients treated at an Indian tertiary care centre.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survival outcomes in prostate cancer patients treated at an Indian tertiary care centre.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is an emerging public health concern in India, with rising incidence and varying survival outcomes. This study aimed to evaluate 5-year overall survival and identify prognostic factors among prostate cancer patients treated at Tata Memorial Hospital (TMH), Mumbai. Methods: This retrospective study included all patients newly diagnosed with prostate cancer between January and December 2017 who received cancer-directed treatment at TMH. Patients were followed through 2022. Clinico-epidemiological variables including age, PSA levels, Gleason grade, clinical extent (EAU risk group classification), intent, completion status and treatment modality were analysed. Kaplan-Meier survival curves and Cox proportional hazards models were used to assess survival outcomes. Results: A total of 421 patients were included, with a mean (SD) age of 66 ± (8.39) years and a median (IQR) PSA of 45.9 (17-154) ng/ml. All patients were symptomatic at presentation, predominantly with urinary complaints (90.5%), followed by bone pain (3.6%) or both (5.9%). At diagnosis, 15.2% had localized disease, 25.8% had locally advanced disease, and 58.4% had metastatic cancer. The overall 5-year survival rate was 61%. Prognostic factors significantly associated with survival included age, PSA, Gleason grade and disease extent. Patients with PSA > 1000 ng/ml had the poorest prognosis (33% 5-year survival). Survival varied by age group, declining from 66% in those aged 66-75 years to 45% in patients >75 years, although this trend was not statistically significant in adjusted analysis ( Conclusion: Survival in prostate cancer is strongly influenced by clinical extent at diagnosis, PSA, Gleason grade and treatment. Improving early detection, expanding multimodal treatment strategies and ensuring treatment completion are critical to enhancing outcomes in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.